The four species of the genus Rochalimaea (Rochalimaea quintana, Rochalimaea henselae, Rochalimaea elizabethae, and Rochalimaea vinsonii) were recently shown to be closely related to the sole member of the genus Bartonella (Bartonella bacilliformis) [1]. Because Bartonella was described before Rochalimaea, the former designation takes precedence over the latter. Thus the name Bartonella will be used in this document to describe all five members of the expanded genus. However, in many publications the name Rochalimaea may still be used. Species names remain unchanged; e.g., R. henselae is now known as Bartonella henselae.
The four species of the genus Rochalimaea (Rochalimaea quintana, Rochalimaea henselae, Rochalimaea elizabethae, and Rochalimaea vinsonii) were recently shown to be closely related to the sole member of the genus Bartonella (Bartonella bacilliformis) [1] . Because Bartonella was described before Rochalimaea, the former designation takes precedence over the latter. Thus the name Bartonella will be used in this document to describe all five members of the expanded genus. However, in many publications the name Rochalimaea may still be used. Species names remain unchanged; e.g., R. henselae is now known as Bartonella henselae.
Background
The diseases known to be associated with Bartonella species are listed in table 1. Historically, the best-known member of the genus is Bartonella quintana, the bacterium that caused trench fever in World War I [2] . In 1990, DNA sequences closely related to B. quintana were identified in the lesions of patients with bacillary angiomatosis (BA) [3] , a vascular proliferative disorder that occurs in HIV-infected persons [4] . Independently, a fastidious gram-negative rod was isolated from HIV-infected patients with a relapsing febrile illness [5] , and similar bacilli were noted in tissue from patients with an unusual hepatic disease known as peliosis hepatis [6] . A novel species, B. henselae, was later isolated and fully characterized [7, 8] . Gene sequences from B. henselae were identical to those previously identified in biopsied tissues from patients with BA and peliosis hepatis [3, 7] . The subsequent isolation of bacteria directly from cutaneous lesions of BA revealed that either B. henselae or B. quintana can cause this disease [9] . Over the past decade, since BA was first described by Stoler et al. in New York City [10] , the spectrum of bartonella infection in patients with concomitant HIV infection has been expanding; now included are endocarditis [11, 12] and angiomatous lesions involving many organs, including the skin, liver, lung, spleen, bone, and brain. (For a summary of the involvement of various organs, see [13] .) Although cutaneous BA can be an indolent disease with remissions and exacerbations over many months [4] , its systemic symptoms can be debilitating. When bartonella infection remains undiagnosed in patients with HIV infection, it can be fatal [14] .
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Recently, B. henselae was found to be the cause of catscratch disease [15] [16] [17] in addition to some cases of BA. The reason for the different host responses to infection with B. henselae (granulomatous in the immunocompetent host and vascular proliferative in the immunocompromised host) is unknown. Immunocompetent people with B. henselae infection can develop a prolonged febrile and relapsing illness [18] like that seen in HIV-infected patients [5, 7] .
Infection with the remaining three Bartonella species has not been reported in HIV-infected patients. Bartonella elizabethae caused severe endocarditis in one immunocompetent patient [19] . No human infections with Bartonella vinsonii have been identified. B. bacilliformis, the etiologic agent of bartonellosis, causes biphasic illness: the acute febrile phase is known as Oroya fever, and the chronic phase with cutaneous vascular lesions is known as verruga peruana [20] . These cutaneous [13] . Rifampin and gentamicin appear to have some clinical efficacy; although there is insufficient evidence to recommend the use of either agent alone, these drugs may be of value when combined with a first-line agent for the treatment of immunocompromised patients with severe Bartonella-associated disease (e.g., osteomyelitis, peliosis hepatis, or endocarditis). There are conflicting reports regarding the response of BA lesions in immunocompromised patients to treatment with quinolones [13] .
The optimal duration of treatment for immunocompromised individuals is unknown, but patients with cutaneous BA should receive an appropriate antibiotic for at least 2 or 3 months; patients with more severe disease (osteomyelitis, peliosis hepatis) should receive a minimum of 3 or 4 months of antibiotic therapy. Most patients treated with tetracycline or erythromycin for 4 months do not have a relapse. However, like salmonellosis and various other bacterial infections, bartonella infection can relapse in some cases even after prolonged therapy with erythromycin [9] . Immunocompromised patients with bartonella infection should be followed closely if antibiotic treatment is stopped after 4 months; if a relapse occurs, these individuals should be treated indefinitely with suppressive antibiotics.
Although the clinical response to antibiotics is dramatic among immunocompromised patients with bartonella infection, the response of people with intact immune systems and catscratch disease or relapsing bacteremia remains equivocal [18, 21] . The curious influence of the host's immune status on apparent antibiotic efficacy may be related to different manifestations of the syndromes. Cat-scratch disease is clinically defined by swollen lymph nodes and granulomatous lesionssigns that cannot develop in severely immunocompromised hosts and that cannot be expected to regress as long as antigen is present. It is possible that persons with intact immune systems, unlike severely immunocompromised patients, sequester viable or antigenically active Bartonella within either cells or immune-mediated tissue complexes (e.g., granulomas).
Incidence
Preliminary estimates of the prevalence of antibody to Bartonella among apparently healthy humans range from 4% to 6% [15, 22] . Cat-scratch disease is clinically diagnosed in an estimated 22,000 persons each year in the United States [23] . The incidence of Bartonella-associated disease among HIVinfected persons is unknown. These infections may go unrecognized in the majority of cases, and the interval between infection and the diagnosis of BA can cover months or even a year [9] . In addition, disease in immunocompromised persons may represent reactivation of infection rather than primary infection: low-titer antibodies to Bartonella have been documented in banked sera obtained from HIV-infected people before the diagnosis of BA, with increased titers at the time of diagnosis [24] .
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Source of Infection and Risk Factors
Numerous anecdotal reports have described exposure to and contact with cats before the development of BA in immunocompromised patients [13] . A case-control analysis found that recent contact with cats was the only environmental risk factor associated with BA [28] . Patients with BA-but not control patients-were statistically more likely to have been licked, scratched, or bitten by a cat before developing this illness. The amount of time spent with a cat was associated with the degree of risk. As had previously been documented in studies of catscratch disease in HIV-uninfected populations [22, 29] , ownership of kittens or young cats (i.e., those <1 year old) posed a particularly high risk to HIV-infected persons for acquiring B. henselae-associated disease [28] .
It has recently been shown that the domestic cat provides a major reservoir from which HIV-infected patients apparently acquire B. henselae infection. Seven pet cats belonging to four patients with confirmed BA due to B. henselae had this organism isolated from the bloodstream, as did 25 (41%) of 61 randomly sampled cats in San Francisco [30] . Seroepidemiological studies indicate that B. henselae infection of domestic cats is also common in other regions of the United States, with a prevalence of Bartonella-specific antibodies ranging from 14% to 50% [22, 31] . An estimated one-third of all households in the United States include a cat [32] , and cats may be persistently bacteremic for prolonged periods without obvious signs of illness [30, 33] . Thus, pet cats pose a real but probably small risk of B. henselae infection to HIV-infected owners [34] .
Exposure to kittens with fleas has been reported to be a risk factor for cat-scratch disease. Thus, it has been suggested that arthropod vectors transmit B. henselae among felines and/or between felines and humans, although a cat scratch or bite has been more strongly associated with acquisition of the disease [22] . Viable B. henselae bacilli have been isolated from fleas from cats [30] , but the fleas' ability to transmit B. henselae has not been established. Ticks also have been suggested as possible vectors of B. henselae [18, 22] .
Early in the investigation of Bartonella-associated diseases, the human body louse (Pediculus humanus) was identified as a vector of human-to-human transmission of B. quintana [2] . The risk of developing relatively severe disease due to Bartonella species appears to increase as the CD4+ cell count decreases. In a recent review, the mean CD4+ cell count of 15 HIV-infected patients with Bartonella-associated disease was 57/mm3 [13] . In a case-control study of 42 patients with bartonella infection, patients with BA were statistically more likely than controls to have a CD4+ cell count of <200/mm3 [35] .
Prevention
Physicians should recognize the potential psychological value of companion animals for seriously ill persons. However, immunocompromised persons who have no prior emotional attachment to a cat and who are concerned about the risk of B. henselae infection should consider alternative species for companionship. Of course, the potential for zoonotic disease associated with nonfeline companion-animal species also must be considered [34] .
Because data are not yet available on the degree of risk to humans for B. henselae infection related to contact with cats or on the mode of B. henselae transmission from one cat to another or from cats to humans, specific recommendations for prevention are currently limited to common-sense precautions [34, 36] . Adult cats pose a lesser risk than do cats <1 year old. Severely immunocompromised persons should avoid rough play with cats that might result in scratches or bites and should not allow a cat to lick open cuts or wounds. Contamination of broken skin with cat secretions should be avoided, and cat-associated wounds should be washed immediately with soap and water. Control of fleas is appropriate.
Recommendations regarding the prevention of B. quintana infection are presently limited to the avoidance of exposure to the human body louse.
Research Priorities
Bartonella-associated disease among HIV-infected persons has been described only recently, but it is already evident that treatment and preventive efforts can be beneficial. The incidence of Bartonella-associated disease must be established, and the spectrum of disease (including syndromes currently undiagnosed) must be more completely elucidated. Economical, rapid, sensitive, and specific methods for laboratory diagnosis need to be further developed and disseminated to local health care centers. The timing, type, and duration of antibiotic prophylaxis for initial or reactivated bartonella infection in HIV-infected persons (especially those who are seropositive for Bartonella) should be considered. The development of microbial resistance is a theoretical possibility during prolonged antimicrobial therapy.
More complete analyses of risk factors for infections due to B. henselae and B. quintana must be undertaken. The route by which cats become infected with B. henselae and the way in which this organism persists in and is subsequently transmitted by these animals should be established. The potential for the elimination of feline infections due to B. henselae by antibiotic treatment and for the prevention of reinfection must be studied. A feline vaccine designed to prevent B. henselae infection should be developed, with the interruption of transmission to HIV-infected pet owners as the ultimate goal. The possible role of arthropod vectors in the transmission of B. henselae and B. quintana needs to be clarified.
